Autoimmune Disease

CTLA-4 and its Role in Regulating Immune Response

Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) prevents overactivation of the immune system and averts potential damage to the body's own cells.


Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), also known as CD152, is a protein receptor that plays a critical role in the regulation of the immune system. It serves as a check and balance mechanism, preventing overactivation of the immune system and averting potential damage to the body's own cells.

Function of CTLA-4

CTLA-4 is primarily expressed on the surface of T cells, and its main function is to downregulate or inhibit the immune response, acting as a 'brake' for T cells.

Upon activation by an antigen, T cells upregulate both CTLA-4 and CD28, a co-stimulatory molecule that enhances T cell responses. Both CTLA-4 and CD28 compete for binding to the same ligands, B7-1 and B7-2, which are found on antigen-presenting cells. However, CTLA-4 has a much higher affinity for these ligands and can outcompete CD28 for binding.

When CTLA-4 binds to B7-1 or B7-2, it sends an inhibitory signal to the T cell, dampening its activation and proliferation. This is in contrast to the stimulatory signal sent by CD28 when it binds to these ligands. In this way, CTLA-4 acts as a counterbalance to CD28, ensuring that the immune response is not excessively activated.

 

CTLA-4 in Disease and Therapy

Given its pivotal role in regulating immune responses, it is not surprising that CTLA-4 has been implicated in various diseases. For instance, genetic mutations that reduce CTLA-4 function have been linked to autoimmune conditions, where the immune system mistakenly attacks the body's own cells.

On the other hand, CTLA-4's immune-inhibitory function can be exploited by cancer cells to evade the immune system. Some cancer cells overexpress B7-1 and B7-2 ligands, engaging CTLA-4 and thereby suppressing the T cell response against them.

This has led to the development of CTLA-4-blocking antibodies, such as ipilimumab, for cancer immunotherapy. By blocking the interaction between CTLA-4 and its ligands, these drugs can 'release the brakes' on the immune system, enhancing the T cell response against cancer cells.

Similar posts

StackWave Affinity™

Whether you're a CRO making customer deliveries, a start-up advancing towards IND, or an established biopharma supporting multiple programs at once, Affinity supports every team, at every step, on a single platform, for a single price.

Download the StackWave Affinity LIMS presentation

Sign up for notifications